BPC-157 may not be appropriate when: Imaging or specialist review has not yet been completed for a suspected structural injury There are acute red flag features (severe weakness, fever, rapid unexplained swelling, neurological changes, unexplained weight loss) The patient has active cancer or a history of certain cancers where angiogenic peptides require careful risk assessment The goal is rapid results without addressing underlying load, rehabilitation, or lifestyle drivers A peptide should not be used to delay evaluation that is clearly warranted
Is BPC-157 FDA approved
Tendon and ligament repair, gastrointestinal mucosal healing, soft tissue recovery, and neuroprotective signaling are all supported by reproducible rodent and in vitro work, while the human evidence remains limited to one unpublished Phase 2 IBD trial and a small number of preliminary studies
Bacterial contamination : Without preservatives, bacteria grow in liquid solutions
While injectable B12 is generally considered more effective, oral supplements are an acceptable alternative depending on the needs of the patient
Persistent symptoms beyond two weeks or severe GI distress (vomiting, diarrhea) suggest reconstitution error or contamination
